US Stock MarketDetailed Quotes
AGEN Agenus
- 3.340
- +0.480+16.78%
Close Nov 22 16:00 ET
- 3.399
- +0.059+1.76%
Post 19:41 ET
78.35MMarket Cap-303P/E (TTM)
3.380High2.784Low1.08MVolume2.790Open2.860Pre Close3.46MTurnover4.65%Turnover RatioLossP/E (Static)23.46MShares19.68852wk High-0.27P/B77.31MFloat Cap2.50052wk Low--Dividend TTM23.15MShs Float8419.554Historical High--Div YieldTTM20.83%Amplitude2.500Historical Low3.214Avg Price1Lot Size
Agenus Stock Forum
Sign in to post a comment
$Agenus (AGEN.US)$
Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024
Agenus (NASDAQ: AGEN) will present new data on two promising immunotherapy candidates at the SITC 2024 Annual Meeting in Houston. The presentations will feature botensilimab, an Fc-enhanced anti-CTLA-4 antibody showing efficacy in treatment-resistant cancers, and AGEN1721, a first-in-class bifunctional antibody targeting FAP and TGFβ.
Botensilimab enhances both innate and adaptive immunity, demonstr...
Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024
Agenus (NASDAQ: AGEN) will present new data on two promising immunotherapy candidates at the SITC 2024 Annual Meeting in Houston. The presentations will feature botensilimab, an Fc-enhanced anti-CTLA-4 antibody showing efficacy in treatment-resistant cancers, and AGEN1721, a first-in-class bifunctional antibody targeting FAP and TGFβ.
Botensilimab enhances both innate and adaptive immunity, demonstr...
1
$Agenus (AGEN.US)$
Botensilimab/Balstilimab Clinical Responses in Refractory Sarcomas Presented at ESMO 2024
Agenus Inc. (Nasdaq: AGEN) presented promising data at the ESMO Congress for their Phase 1 study of botensilimab (BOT) and balstilimab (BAL) combination in refractory sarcomas. Key findings include:
- 23% overall response rate (ORR) in the full sarcoma cohort
- 21.7 months median duration of response (DOR)
- 69% 12-month overall survival (OS)
- 39% ORR in angiosarcoma subtype
- Managea...
Botensilimab/Balstilimab Clinical Responses in Refractory Sarcomas Presented at ESMO 2024
Agenus Inc. (Nasdaq: AGEN) presented promising data at the ESMO Congress for their Phase 1 study of botensilimab (BOT) and balstilimab (BAL) combination in refractory sarcomas. Key findings include:
- 23% overall response rate (ORR) in the full sarcoma cohort
- 21.7 months median duration of response (DOR)
- 69% 12-month overall survival (OS)
- 39% ORR in angiosarcoma subtype
- Managea...
$Agenus (AGEN.US)$ Agenus Sued by Shareholder for Misleading Investors Over Colorectal Cancer Immuno-Therapy Trial Results
MT Newswires· 10 mins ago
Agenus (AGEN) is being accused of misleading investors in public comments about a combination of two prospective treatments for cancer in a new shareholder suit filed last week in federal court in Massachusetts.
The Boston-area biotech company has been working to develop several new immuno...
MT Newswires· 10 mins ago
Agenus (AGEN) is being accused of misleading investors in public comments about a combination of two prospective treatments for cancer in a new shareholder suit filed last week in federal court in Massachusetts.
The Boston-area biotech company has been working to develop several new immuno...
4
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Agenus (AGEN.US)$
Botensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024
Agenus Inc. (Nasdaq: AGEN) announced that updated data from the clinical trial of botensilimab and balstilimab in refractory sarcomas will be presented at the ESMO Congress 2024 in Barcelona. The presentation will showcase updated efficacy and safety data from the ongoing Phase 1 trial, highlighting the potential of this combination therapy in treating patients wit...
Botensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024
Agenus Inc. (Nasdaq: AGEN) announced that updated data from the clinical trial of botensilimab and balstilimab in refractory sarcomas will be presented at the ESMO Congress 2024 in Barcelona. The presentation will showcase updated efficacy and safety data from the ongoing Phase 1 trial, highlighting the potential of this combination therapy in treating patients wit...
$Agenus (AGEN.US)$
Agenus Publishes Seminal Study on Botensilimab’s Activity in Treatment-Resistant Cancers
Agenus Inc. (NASDAQ: AGEN) has published a groundbreaking study in Cancer Discovery on botensilimab, their novel Fc-enhanced anti-CTLA-4 antibody. The study highlights botensilimab's effectiveness against treatment-resistant cancers, including those unresponsive to conventional immunotherapy. Key findings include:
1. Demonstrated activity across multiple cancer types
2. Unique Fc-enhanc...
Agenus Publishes Seminal Study on Botensilimab’s Activity in Treatment-Resistant Cancers
Agenus Inc. (NASDAQ: AGEN) has published a groundbreaking study in Cancer Discovery on botensilimab, their novel Fc-enhanced anti-CTLA-4 antibody. The study highlights botensilimab's effectiveness against treatment-resistant cancers, including those unresponsive to conventional immunotherapy. Key findings include:
1. Demonstrated activity across multiple cancer types
2. Unique Fc-enhanc...
1
$Agenus (AGEN.US)$ why the calls are so cheap?
$Agenus (AGEN.US)$
BID AND ASK TO FAR MUST SELL ALL AND DELETE 👹🗡️🔥👺💣
BID AND ASK TO FAR MUST SELL ALL AND DELETE 👹🗡️🔥👺💣
2
$Agenus (AGEN.US)$ gap up next week from overselling
2
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Krystian 1983 : Martin from Denmark
day trader
Krystian 1983 : This go to be at 10 dollars in december
